Stereotactic ablative radiotherapy appeared to improve clinical outcomes compared with observation among men with oligometastatic prostate cancer, according to results of the randomized phase 2 ORIOLE study published in JAMA Oncology.

The treatment was enhanced by total consolidation of disease identified by prostate-specific membrane antigen-targeted PET and induced a systemic immune response. Baseline immune phenotype and tumor mutation status may help predict benefits of stereotactic ablative radiotherapy (SABR) for these men, researchers noted.